Uploaded March 2026 | Updated September 2026, 3 weeks ago
Could the next generation of GLP-1 drugs give us all the benefits — with none of the nausea? New research out of the University of Pennsylvania says it might be possible.
Scientists at Penn's School of Nursing and Perelman School of Medicine just published a study on a compound called Ex-Phe-1 — a modified GLP-1 receptor agonist that uses a mechanism called "biased agonism" to selectively activate only the pathways that control blood sugar, while dialing back the ones that cause nausea and vomiting.
In this episode of The Weekly Shot, RMZ breaks down what this means for the 1 in 8 Americans currently on a GLP-1 drug like Zepbound, Ozempic, or Wegovy — and why this research could be a game-changer for people who've struggled with side effects.
In this video:
What biased agonism actually means (in plain English)
Why nausea happens on GLP-1s — and which signaling pathway causes it
What the Penn study found in preclinical models
Why this matters especially for diabetic patients with cancer or HIV
What comes next for this research
Penn Study: https://tr.ee/zeUTiT
⚠️ This video is for informational purposes only and is not medical advice. Always consult your healthcare provider before making any changes to your medication.
🔔 Subscribe for weekly GLP-1 news, men's health updates, and the real talk behind the journey.
📲 Follow RMZ on Instagram & TikTok for short-form clips from this episode.
Social Links
tiktok.com/@roundmoundofzepbound
instagram.com/roundmoundofzepbound
#glp1#zepbound #mounjaro #weightloss #weightlossjourney #glp #tirzepatide #semaglutide #wegovy #ozempic #menshealth #beforeandafter #beforeandafterweightloss
Could the next generation of GLP-1 drugs give us all the benefits — with none of the nausea? New research out of the University of Pennsylvania says it might be possible.
Scientists at Penn's School of Nursing and Perelman School of Medicine just published a study on a compound called Ex-Phe-1 — a modified GLP-1 receptor agonist that uses a mechanism called "biased agonism" to selectively activate only the pathways that control blood sugar, while dialing back the ones that cause nausea and vomiting.
In this episode of The Weekly Shot, RMZ breaks down what this means for the 1 in 8 Americans currently on a GLP-1 drug like Zepbound, Ozempic, or Wegovy — and why this research could be a game-changer for people who've struggled with side effects.
In this video:
What biased agonism actually means (in plain English)
Why nausea happens on GLP-1s — and which signaling pathway causes it
What the Penn study found in preclinical models
Why this matters especially for diabetic patients with cancer or HIV
What comes next for this research
Penn Study: https://tr.ee/zeUTiT
⚠️ This video is for informational purposes only and is not medical advice. Always consult your healthcare provider before making any changes to your medication.
🔔 Subscribe for weekly GLP-1 news, men's health updates, and the real talk behind the journey.
📲 Follow RMZ on Instagram & TikTok for short-form clips from this episode.
Social Links
tiktok.com/@roundmoundofzepbound
instagram.com/roundmoundofzepbound
#glp1#zepbound #mounjaro #weightloss #weightlossjourney #glp #tirzepatide #semaglutide #wegovy #ozempic #menshealth #beforeandafter #beforeandafterweightloss
